Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Fred Khosravi and AccessClosure (C)
Hamermesh, Richard G.; Barley, LaurenCaso HBS-814074-EIniciativa emprendedoraOn September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It wa...Desde 5,74 €
-
Whose Money Is It Anyway (C)
Narayanan, V.G.; Hamermesh, Richard G.; Gordon, RachelCaso HBS-810031-EContabilidad y controlThe case describes how the Brigham and Women's Physicians Organization and its corporate parent resolved the issue of how the disputed funds would be distributed and used.Desde 5,74 €
-
Whose Money Is It Anyway (A), (B), and (C), Teaching Note
Hamermesh, Richard G.; Narayanan, V.G.; Gordon, RachelNota del Instructor HBS-111128-EContabilidad y controlTeaching Note for 810-008, 810-013, and 810-031.Desde 0,00 €
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCaso HBS-813037-EIniciativa emprendedoraThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Desde 8,20 €
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Caso HBS-302S36Conocimiento y comunicaciónDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Desde 8,20 €
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCaso HBS-815114-EIniciativa emprendedoraIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Desde 8,20 €
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCaso HBS-813091-EIniciativa emprendedoraSupplement for case 809011Desde 8,20 €
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCaso HBS-810027-EIniciativa emprendedoraNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Desde 8,20 €
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCaso HBS-818068-EDirección estratégicaDesde 8,20 €
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCaso HBS-811089-EIniciativa emprendedoraIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Desde 8,20 €